The new shares will be subscribed by some German and European family offices in full. The subscription price per new share is EUR 1.64. The statutory subscription rights have been excluded pursuant to Sec. 186 Para. 3 sentence 4 of the German Stock Corporation Act (Aktiengesetz).

Upon successful completion of the capital increase which is currently scheduled for 30 November 2020, 4SC will obtain total net proceeds of approximately EUR 7.5 million. Trading of the new shares on the Frankfurt Stock Exchange is anticipated to commence on 1 December 2020 after registration of the implementation of the capital increase with the commercial register, which is expected to occur on 30 November 2020.

Information and explanation of the Issuer to this news:

Dr. Jason Loveridge, CEO, commented; "We’re very pleased to be able to increase our cash balance with support from both our main shareholder as well as new investors. This capital injection will provide us with funds to execute on our drug development programs into 2022 and we now look forward to seeing significant clinical outcomes for both domatinostat and resminostat over the next 18 months."

Forward-looking information

Information set forth in this ad-hoc release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this ad-hoc release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Disclaimer

This ad-hoc release constitutes neither an offer to sell nor a solicitation to buy securities.
In particular, this publication is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act") or an exemption from registration. The Shares have not been and will not be registered under the Securities Act.
Neither this ad-hoc release nor any copy of it (nor in whole or in part) may be released, distributed, published or transmitted, directly or indirectly, into the United States, Australia, Canada, Japan, South Africa, or any other jurisdiction where it is unlawful to distribute this announcement. This ad-hoc release does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefore.